```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptajs11623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02  LMEDLINE coverage updated
 NEWS  3  JUL 02  SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02  CHEMCATS accession numbers revised
 NEWS  5  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16  CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18  CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30  USGENE now available on STN
 NEWS 10  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 13  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 15  AUG 27  USPATOLD now available on STN
 NEWS 16  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data
 NEWS 17  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                  World Patents Index
 NEWS 18  SEP 13  FORIS renamed to SOFIS
 NEWS 19  SEP 13  INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17  CA/CAplus enhanced with printed CA page images from
                  1967-1998
 NEWS 21  SEP 17  CAplus coverage extended to include traditional medicine
                  patents
 NEWS 22  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                  Zentralblatt
 NEWS 24  OCT 19  BEILSTEIN updated with new compounds

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
```

FILE 'HOME' ENTERED AT 08:05:54 ON 14 NOV 2007

=> b reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:06:07 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2
DICTIONARY FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\jlaul\My Documents\10509675 - arthritis\species
structure.str



chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-7 10-13 12-24 13-14 13-15 14-22 15-16 15-21 16-17 17-18 18-19 19-20 19-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
15-16 15-21 18-19 19-20 19-23
exact bonds :

```
5-7  10-13  12-24  13-14  13-15  14-22  16-17  17-18
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom  11:Atom
12:Atom  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS  20:CLASS
21:CLASS  22:CLASS  23:CLASS  24:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 08:06:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED         0 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO         0
PROJECTED ANSWERS:               0 TO         0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:06:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        9 TO ITERATE

100.0% PROCESSED         9 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1
```

```
=> logoff hold
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       172.10     172.31

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:06:55 ON 14 NOV 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 08:55:38 ON 14 NOV 2007
FILE 'REGISTRY' ENTERED AT 08:55:38 ON 14 NOV 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       172.10     172.31

=>
Uploading C:\Documents and Settings\jlaul\My Documents\10509675 - arthritis\flurbiprofen
exact.str
```





```
chain nodes :
13  14  15  16  17  18
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12
chain bonds :
5-7  10-13  12-18  13-14  13-17  14-15  14-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12
exact/norm bonds :
14-15  14-16
exact bonds :
5-7  10-13  12-18  13-14  13-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom  11:Atom
12:Atom  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
```

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4 exact sam
SAMPLE SEARCH INITIATED 08:56:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 1 TO 80

L5 1 SEA EXA SAM L4

=> d l5 scan

L5 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl-
MF C15 H13 F O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 173.00 | 173.21

FILE 'CAPLUS' ENTERED AT 08:57:03 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 13 Nov 2007 (20071113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5
L6 2879 L5

=> s l6 and py<=2003
23955884 PY<=2003
L7 2138 L6 AND PY<=2003

=> s l7 and nitroso
29844 NITROSO
16 NITROSOS
29849 NITROSO
(NITROSO OR NITROSOS)
L8 3 L7 AND NITROSO

=> d l8 scan

L8 3 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
IC ICM A61K031-54
ICS C07D513-00; C07D513-02; C07D513-04
CC 1-7 (Pharmacology)
Section cross-reference(s): 25, 27, 28, 63
TI Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
ST NO substituted NSAID prepn antiinflammatory analgesic; antipyretic NO substituted NSAID prepn; gastrointestinal disorder NO substituted NSAID prepn; toxicity NSAID prevention NO substituted NSAID
IT Analgesics
Antipyretics
Toxicity
(NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)
IT Thiols (organic), biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(S-nitroso; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Digestive tract
(disease, lesion; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Amino acids, biological studies
Aromatic hydrocarbons, biological studies
Carbohydrates, biological studies
Hydrocarbons, biological studies
Oligonucleotides
Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxynitrosohydrazine-containing; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Anti-inflammatory agents
(nonsteroidal; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Nitrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thio-; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Digestive tract
Kidney
(toxicity; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen
RL: ADV (Adverse effect, including toxicity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Acetylsalicylic acid 54-21-7, Sodium salicylate 58-15-1, Aminopyrine 60-80-0, Antipyrine 61-68-7, Mefenamic acid 62-44-2, Phenacetin 65-45-2, Salicylamide 68-89-3, Dipyrone 69-72-7D, Salicylic acid, derivs. 89-57-6, Mesalamine 103-82-2D, Phenylacetic acid, derivs. 103-90-2, Acetaminophen 119-36-8, Methyl salicylate 120-72-9D, Indole, derivs. 123-30-8D, p-Aminophenol, derivs. 129-20-4, Oxyphenbutazone 142-29-0D, Cyclopentene, diaryl derivs. 530-78-9, Flufenamic acid 552-94-3, Salsalate 599-79-1, Sulfasalazine 644-62-2, Meclofenamic acid 2016-36-6, Choline salicylate, biological studies 5104-49-4, Flurbiprofen 7048-08-0, Sodium thiosalicylate 12766-00-6D, Quinazolinone, derivs. 13539-59-8, Apazone 13710-19-5, Tolfenamic acid 15307-86-5, Diclofenac 18917-89-0, Magnesium salicylate 21256-18-8, Oxaprozin 22494-42-4, Diflunisal 22760-18-5, Proquazone 26171-23-3, Tolmetin 29679-58-1, Fenoprofen 30544-47-9, Etofenamate 31793-07-4, Pirprofen 31842-01-0, Indoprofen 33005-95-7, Tiaprofenic acid 34552-84-6, Isoxicam 36322-90-4, Piroxicam 36330-85-5, Fenbufen 38194-50-2, Sulindac 39455-90-8D, Pyrazolone, derivs. 41340-25-4, Etodolac 42924-53-8, Nabumetone 55843-86-2, Miroprofen 59804-37-4, Tenoxicam 80937-31-1, CGP 28238 88149-94-4, DuP 697 120210-48-2, Tenidap 123653-11-2, NS-398 158205-05-1, L-745337 158959-32-1 162054-19-5, SC-58125

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 6316-86-5P 6709-70-2P 57564-91-7P 184473-91-4P 184473-93-6P
184473-96-9P 184474-00-8P 184474-06-4P 184474-10-0P 184474-14-4P
184474-18-8P 184474-22-4P 184474-26-8P 184474-30-4P 184474-36-0P
184474-38-2P 184474-40-6P 184474-42-8P 184474-46-2P 184474-48-4P
184474-50-8P 184474-54-2P 184474-58-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 10102-43-9, Nitrogen monoxide, biological studies 14452-93-8, Nitrosonium 155557-95-2D, derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 39391-18-9, Cyclooxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 17071-62-4P 17768-28-4P 51091-84-0P 59512-44-6P 70458-50-3P
89031-83-4P 90466-78-7P, 5-Acetoxyisophthalic acid 184473-92-5P
184473-94-7P 184473-98-1P 184474-04-2P 184474-07-5P 184474-12-2P
184474-16-6P 184474-20-2P 184474-24-6P 184474-29-1P 184474-32-6P
184474-33-7P 184474-34-8P 184474-35-9P 184474-37-1P 184474-39-3P
184474-41-7P 184474-43-9P 184474-45-1P 184474-47-3P 184474-49-5P
184474-51-9P 184474-52-0P 184474-53-1P 184474-55-3P 184474-56-4P
184474-57-5P 184474-59-7P 184474-60-0P 184474-61-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 57-88-5, Cholesterol, reactions 79-37-8, Oxalyl chloride 107-88-0, 1,3-Butanediol 108-24-7, Acetic anhydride 108-30-5, reactions 110-63-4, 1,4-Butanediol, reactions 121-91-5, 1,3-Benzenedicarboxylic acid, reactions 540-80-7, tert-Butyl nitrite 589-29-7, 1,4-Benzenedimethanol 928-51-8, 4-Chloro-1-butanol 1462-10-8, 2-Methyl-2,5-pentanediol 3262-72-4 3695-77-0, Triphenylmethyl mercaptan 7632-00-0, Sodium nitrite 10387-40-3, Potassium thioacetate 10544-72-6, Dinitrogen tetroxide 14635-75-7, Nitrosonium tetrafluoroborate 18162-48-6, tert-Butyldimethylsilyl chloride 24785-71-5 26159-34-2 32047-53-3 34300-94-2, 3-Mercapto-3-methylbutanol 39269-10-8, 1,3-Adamantanedicarboxylic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d l8 and arthritis
'AND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
'ARTHRITIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB

```
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> s l8 and arthritis
         49311 ARTHRITIS
             2 ARTHRITISES
         49311 ARTHRITIS
                   (ARTHRITIS OR ARTHRITISES)
L9           0 L8 AND ARTHRITIS
```

```
=> d l8 1-3 ibib abs

L8   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2000:259972  CAPLUS
DOCUMENT NUMBER:          132:293042
TITLE:                    Encapsulation of sensitive liquid components into a
                          matrix to obtain discrete shelf-stable particles
INVENTOR(S):              Van Lengerich, Bernhard H.
PATENT ASSIGNEE(S):       General Mills, Inc., USA
SOURCE:                   PCT Int. Appl., 56 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     WO 2000021504        A1    20000420    WO 1999-US20905        19991006 <--
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 7201923           B1    20070410    US 1999-233443         19990120
     CA 2345815           A1    20000420    CA 1999-2345815        19991006 <--
     AU 9963872           A     20000501    AU 1999-63872          19991006 <--
     AU 777977            B2    20041104
     EP 1119345           A1    20010801    EP 1999-951433         19991006 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002527375        T     20020827    JP 2000-575480         19991006 <--
PRIORITY APPLN. INFO.:                       US 1998-103700P     P  19981009
                                             US 1998-109696P     P  19981124
                                             US 1999-233443      A  19990120
                                             WO 1999-US20905     W  19991006
AB   A liquid encapsulant component which contains an active, sensitive
     encapsulant, such as a live microorganism or an enzyme dissolved or
     dispersed in a liquid plasticizer is admixed with a plasticizable matrix
     material.  The matrix material is plasticizable by the liquid plasticizer
     and the encapsulation of the active encapsulant is accomplished at a low
     temperature and under low shear conditions.  The active component is
     encapsulated and/or embedded in the plasticizable matrix component or
     material in a continuous process to produce discrete, solid particles.
     The liquid content of the liquid encapsulant component provides substantially
     all or completely all of the liquid plasticizer needed to plasticize the
     matrix component to obtain a formable, extrudable, cuttable, mixture or
     dough.  Removal of liquid plasticizer prior to extrusion is not needed to
     adjust the viscosity of the mixture for formability.  Release of an active
     component from the matrix may be delayed or controlled over time so that
     the active component is delivered when and where it is needed to perform
     its intended function.  Controlled release, discrete, solid particles
     which contain an encapsulated and/or embedded component such as a heat
     sensitive or readily oxidizable pharmaceutically, biol., or nutritionally
     active component are continuously produced without substantial destruction
     of the matrix material or encapsulant.
REFERENCE COUNT:          1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1999:404846  CAPLUS
DOCUMENT NUMBER:          131:39763
TITLE:                    The use of nitric oxide generators for the treatment
```

of dry eye disorders
INVENTOR(S): Gamache, Daniel A.; Miller, Steven T.; Yanni, John M.
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930716	A1	19990624	WO 1998-US23806	19981110 <--
W: AU, BR, CA, JP, MX, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9913889	A	19990705	AU 1999-13889	19981110 <--
PRIORITY APPLN. INFO.:			US 1997-69711P	P 19971216
			WO 1998-US23806	W 19981110

AB Compns. containing a nitric oxide generator (NOG) and methods of use for treating dry eye are disclosed. The compds. of the invention promote NO production when administered to the eye. It is believed that NO stimulates mucin production in human conjunctival epithelium and are therefore believed to be useful in treating dry eye. A further requirement of a NOG of the invention is that it stimulates mucin production and/or secretion of the conjunctival epithelium and/or ocular goblet cells following topical ocular application. Examples of NOGs include nitroglycerin, sodium nitroprusside, spermine NONOate, (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (FK-409), l-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-l-triazene (NOC-7), S-nitrosoglutathione, 4-phenyl-3-furoxancarbonitrile, S-*nitroso*-N-acetyl-penicillamine (SNAP), isosorbide dinitrate, GEA 3268, GEA 5145, GEA 3175, glyceryl trinitrate, molsidomine, 3-morpholinosydnonimine (SIN-l), hydroxylamine, linsidomine, NOC-18, CHF-2363, pirsidomine, N,N'-dimethylhexanediamine (DMHD/NO), 2,2-diethyl-l-*nitroso*-oxyhydrazine (DEA/NO), Et 2NN(O)NONa, NO-ketoprofen, NO-diclofenac, NO-flurbiprofen. The most preferred NOG of the invention is molsidomine.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:756296 CAPLUS
DOCUMENT NUMBER: 126:14758
TITLE: Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
INVENTOR(S): Garvey, David S.; Letts, L. Gordon; Renfroe, H. Burt; Tam, Sang W.
PATENT ASSIGNEE(S): Nitromed, Inc., USA; Garvey, David S.; Letts, L. Gordon; Renfroe, H. Burt; Tam, Sang W.
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632946	A1	19961024	WO 1996-US4931	19960411 <--
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6051588	A	20000418	US 1995-425090	19950419 <--
US 5703073	A	19971230	US 1995-543208	19951013 <--
AU 9654493	A	19961107	AU 1996-54493	19960411 <--
AU 710951	B2	19990930		
EP 821589	A1	19980204	EP 1996-911685	19960411 <--

```
        R:  CH, DE, FR, GB, IT, LI, SE
     JP 11509519          T     19990824    JP 1996-531797          19960411 <--
     US 6043232           A     20000328    US 1999-235802          19990122 <--
     US 6143734           A     20001107    US 2000-495251          20000131 <--
     AU 773374            B2    20040520    AU 2001-91447           20011121
PRIORITY APPLN. INFO.:                      US 1995-425090      A   19950419
                                            US 1995-543208      A   19951013
                                            WO 1996-US4931      W   19960411
                                            US 1997-899238      A3  19970723
                                            US 1999-235802      A1  19990122
                                            AU 1999-65551       A3  19991230
OTHER SOURCE(S):         MARPAT 126:14758
AB   Nonsteroidal antiinflammatory drugs which have been substituted with a
     nitrogen monoxide group; compns. comprising: (i) a nonsteroidal
     antiinflammatory drug, which can optionally be substituted with a nitrogen
     monoxide group and (ii) a compound that directly donates, transfers or
     releases a nitrogen monoxide group (preferably as a charged species,
     particularly nitrosonium); and methods of treatment of inflammation, pain,
     gastrointestinal lesions and/or fever using the compns. are disclosed.
     The compds. and compns. protect against the gastrointestinal, renal and
     other toxicities that are otherwise induced by nonsteroidal
     antiinflammatory drugs.  Preparation of compds. of the invention is included,
     as are comparative in vivo analgesic,antiinflammatory, and gastric lesion
     activities.


=> d his

     (FILE 'HOME' ENTERED AT 08:05:54 ON 14 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 08:06:07 ON 14 NOV 2007
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM
L3           0 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5           1 S L4 EXACT SAM

     FILE 'CAPLUS' ENTERED AT 08:57:03 ON 14 NOV 2007
L6        2879 S L5
L7        2138 S L6 AND PY<=2003
L8           3 S L7 AND NITROSO
L9           0 S L8 AND ARTHRITIS

=> d l1
L1 HAS NO ANSWERS
L1             STR
```



Structure attributes must be viewed using STN Express query preparation.

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> log off hold
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:58:53 ON 14 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:

```
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 09:03:02 ON 14 NOV 2007
FILE 'CAPLUS' ENTERED AT 09:03:02 ON 14 NOV 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      15.93     189.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.34      -2.34

=> b registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      15.93     189.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.34      -2.34

FILE 'REGISTRY' ENTERED AT 09:03:12 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 NOV 2007  HIGHEST RN 953361-13-2
DICTIONARY FILE UPDATES:  13 NOV 2007  HIGHEST RN 953361-13-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d his

     (FILE 'HOME' ENTERED AT 08:05:54 ON 14 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 08:06:07 ON 14 NOV 2007
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM
L3           0 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5           1 S L4 EXACT SAM

     FILE 'CAPLUS' ENTERED AT 08:57:03 ON 14 NOV 2007
L6        2879 S L5
L7        2138 S L6 AND PY<=2003
L8           3 S L7 AND NITROSO
L9           0 S L8 AND ARTHRITIS

     FILE 'REGISTRY' ENTERED AT 09:03:12 ON 14 NOV 2007
```

```
=> d l5

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   5104-49-4  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   4-Biphenylacetic acid, 2-fluoro-α-methyl- (8CI)
CN   Hydratropic acid, 3-fluoro-4-phenyl- (7CI)
OTHER NAMES:
CN   (±)-Flurbiprofen
CN   2-(2-Fluoro-1,1'-biphenyl-4-yl)propanoic acid
CN   2-(2-Fluoro-4-biphenyl)propionic acid
CN   2-(2-Fluoro-4-biphenylyl)propanoic acid
CN   2-(2-Fluoro-4-biphenylyl)propionic acid
CN   2-Fluoro-α-methyl-4-biphenylacetic acid
CN   2-Fluoro-α-methyl-4-diphenylacetic acid
CN   3-Fluoro-4-phenylhydratropic acid
CN   Adfeed
CN   Ansaid
CN   Antadys
CN   BTS 18322
CN   Cebutid
CN   dl-2-(2-Fluoro-4-biphenylyl)propionic acid
CN   dl-Flurbiprofen
CN   Flugalin
CN   Flurbiprofen
CN   Flurofen
CN   FP 70
CN   FP-A
CN   Froben
CN   rac-Flurbiprofen
CN   Racemic flurbiprofen
CN   Stayban
CN   U 27182
CN   Zepolas
DR   51543-38-5, 79212-68-3
MF   C15 H13 F O2
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,
       CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB,
       IFIPAT, IFIUDB, IMSCOSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS,
       PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE,
       TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

          2863 REFERENCES IN FILE CA (1907 TO DATE)
           113 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          2879 REFERENCES IN FILE CAPLUS (1907 TO DATE)
             1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)
```

```
=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.85     191.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -2.34

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:04:07 ON 14 NOV 2007
```